$3.0m CRC-P grant to VivaZome Therapeutics and Partners for Customised Exosome Therapy
Posted: 24 January VivaZome Therapeutics Pty Ltd is delighted to announce that it has been awarded an Australian Government Round 13 CRC-P grant of $3.0m in support of the project “Customised exosomes – the future of regenerative medicine”.…
Adherium has commenced production and market release of the new, next generation Ellipta sensor
Posted: 23 January Adherium Limited, a leader in respiratory eHealth, remote patient monitoring and data management solutions, is pleased to announce that it has commenced production and market release of the new, next generation Hailie sensors with physiological…
Nasodine research points to potential role in CRS
Posted: 23 January We are pleased to announce the publication of new research into Nasodine Nasal Spray (“Nasodine”) identifying its potential in the management of chronic rhinosinusitis (CRS). Sponsored by Firebrick, the research was conducted at the University…
DARRT-2 Trial Efficacy Phase to Commence
Posted: 23 January Innovative Australian biotech Noxopharm Limited announces the DARRT-2 Safety Steering Committee has reviewed safety data from the third cohort of patients from the dose escalation part of the DARRT-2 trial. The DARRT-2 Phase 2 trial…
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
Posted: 23 January Amplia Therapeutics Limited is pleased to advise that following a review of safety data collected to date, the ACCENT clinical trial’s Safety Review Committee has approved dose escalation of AMP945 and recruitment of another patient…
Monash University and Ono Pharmaceutical Announce Collaboration Agreement
Posted: 23 January An Option and Research Collaboration Agreement has been established between Monash University and Japan-based Ono Pharmaceutical Co. Ltd, which brings together extensive expertise in the discovery and development of antibodies targeting G protein-coupled receptors (GPCRs)…
FDA Includes Paediatric Patients in Dimerix Phase 3 FSGS Study
Posted: 13 January Dimerix Limited, a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, confirmed the outcomes of a meeting with the US Food and Drug Administration (FDA) to discuss the paediatric plan for DMX-200 in Focal…
Cartherics granted first patent in China for multiple development candidates
Posted: 9 January 2023 Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This…
Starpharma receives $7.1M research and development tax incentive refund
Posted: 9 January 2023 Starpharma Holdings Limited announces it has received a $7.1M research and development (R&D) tax incentive refund under the Australian Federal Government’s R&D Tax Incentive scheme. The tax refund relates to Starpharma’s Australian and international…
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
Posted: 9 January 2023 Immutep announces the results of a positive follow-up Type C meeting with the US Food and Drug Administration (FDA) regarding late-stage clinical development plans for its first-in-class soluble LAG-3 protein, eftilagimod alpha (“efti”), in…
Cartherics to Present at Biotech Showcase 2023
Posted: 9 January 2023 Dr Ian Nisbet will provide a presentation on Cartherics’ technology and development program at Biotech Showcase, with a view to engaging with potential investors and partners Cartherics, a biotechnology company developing immune cell therapies…
Ethics Approval received for Phase III Clinical Trial
Posted: 9 January 2023 Avecho Biotechnology Limited has announced that it has now received ethics approval for our Phase III clinical trial, testing oral CBD softgel capsule for insomnia. Avecho is on track to commence the largest randomised,…
